Author | Simon Chowdhury, MA, MBBS, MRCP, PhD | OncLive

Author | Simon Chowdhury, MA, MBBS, MRCP, PhD

Articles

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

July 12, 2017

Video

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

x